Dr. Lal PathLabs Limited

Equities

LALPATHLAB

INE600L01024

Healthcare Facilities & Services

Delayed NSE India S.E. Other stock markets 01:11:28 2024-04-30 am EDT			5-day change	1st Jan Change
2,364 ^INR	+0.71%		+5.10%	-8.28%

Apr. 26	Dr. Lal Pathlabs Limited Announces Resignation of Bharath U as Chief Executive Officer, Effective May 9, 2024	CI
Mar. 18	Dr Lal Pathlabs Names CEO	MT

Dr. Lal PathLabs Limited Approves Second Interim Dividend for the Fiscal Year 2023-24

February 01, 2024 at 03:15 am EST

Dr. Lal PathLabs Limited announced that at its board meeting held on February 01, 2024, shareholders approved the payment of 2nd Interim Dividend of INR 12/- per equity share (@ 120% on a face value of INR 10/- per share) for the fiscal year 2023-24. The record date for the purpose of payment of 2nd Interim Dividend shall be February 13, 2024.

Latest news about Dr. Lal PathLabs Limited

Dr. Lal Pathlabs Limited Announces Resignation of Bharath U as Chief Executive Officer, Effective May 9, 2024	Apr. 26	CI
Dr Lal Pathlabs Names CEO	Mar. 17	MT
Dr. Lal PathLabs Limited Appoints Shankha Banerjee as Chief Executive Officer, Effective May 21, 2024	Mar. 16	CI
Dr. Lal Pathlabs Limited Announces Resignation of Bharath U as Chief Executive Officer	Mar. 03	CI
Nomura Adjusts Dr. Lal Pathlabs’ Price Target to INR2,505 From INR2,465, Keeps at Neutral	Feb. 05	MT
Dr. Lal Pathlabs' Consolidated Profit Jumps in Fiscal Q3; EPS, Revenue Miss Estimates	Feb. 01	MT
Dr. Lal PathLabs Seeks M&A	Feb. 01	CI
Transcript : Dr. Lal PathLabs Limited, Q3 2024 Earnings Call, Feb 01, 2024	Feb. 01
India's Dr. Lal PathLabs posts 54% jump in Q3 profit on flu, COVID tests	Feb. 01	RE
Dr. Lal PathLabs Limited Approves Second Interim Dividend for the Fiscal Year 2023-24	Feb. 01	CI
Dr. Lal PathLabs Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 01	CI
Dr. Lal Pathlabs Board to Consider Second Interim Dividend for Fiscal 2024	Jan. 25	MT
Nomura Upgrades Dr. Lal Pathlabs to Neutral From Reduce, Adjusts Price Target to INR2,465 From INR,2002	Nov. 06	MT
Dr Lal Pathlabs' Consolidated Profit Jumps in Fiscal Q2; Shares Climb 5%	Nov. 03	MT
Transcript : Dr. Lal PathLabs Limited, H1 2024 Earnings Call, Nov 02, 2023	Nov. 02
Dr. Lal PathLabs Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 02	CI
Dr. Lal Pathlabs Limited Approves to Declare Final Dividend for the Financial Year Ended March 31, 2023	23-09-12	CI
Dr. Lal PathLabs Limited Announces Change in Directorate	23-08-20	CI
Dr Lal Pathlabs' Consolidated Profit Jumps in Fiscal Q1; Revenue Meets Estimates	23-07-31	MT
Nomura Downgrades Dr. Lal Pathlabs to Reduce From Neutral, Adjusts Price Target to INR2,002 From INR1,835	23-07-31	MT
Dr. Lal PathLabs Seeks Inorganic Opportunity	23-07-27	CI
Transcript : Dr. Lal PathLabs Limited, Q1 2024 Earnings Call, Jul 27, 2023	23-07-27
Dr. Lal Pathlabs Limited Proposes Interim Dividend for the Financial Year 2023-24	23-07-27	CI
Dr. Lal PathLabs Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-07-27	CI
Dr. Lal PathLabs Limited acquired additional 10% stake in Aprl Pathlabs Private Limited.	23-07-26	CI

Chart Dr. Lal PathLabs Limited

Duration

Period

More charts

Company Profile

Dr. Lal PathLabs Limited is an India-based company that is engaged in providing diagnostic and related healthcare tests and services. The Company is engaged in the business of running laboratories for carrying out pathological investigations of various branches of biochemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. It offers a range of tests by condition, which includes allergy, diabetes, health checkups, viral infections, fever, heart diseases, hypertension, cancer, abortions, anemia, arthritis, breast cancer, diphtheria, disorder of the liver, disorders of bone, drugs of abuse, infertility, lymphoma, tuberculosis, ovarian cancer, osteoporosis, multiple sclerosis, muscular disorder, and viral infections. The Companyâs subsidiaries include Paliwal Diagnostics Private Limited, Paliwal Medicare Private Limited, and Dr. Lal PathLabs Nepal Private Limited.

Sector

Healthcare Facilities & Services

Calendar

2024-05-16 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Dr. Lal PathLabs Limited

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

2,347 INR

Average target price

2,455 INR

Spread / Average Target

+4.60%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical & Diagnostic Laboratories

	1st Jan change	Capi.
DR. LAL PATHLABS LIMITED	-8.28%	2.34B
SONIC HEALTHCARE LIMITED	-16.49%	8.43B
RADNET, INC.	+40.93%	3.62B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-35.59%	2.61B
SYNLAB AG	-7.88%	2.48B
NEOGENOMICS, INC.	-5.93%	1.94B
FLEURY S.A.	-18.96%	1.56B
DIAN DIAGNOSTICS GROUP CO.,LTD.	-38.35%	1.26B
METROPOLIS HEALTHCARE LIMITED	+6.91%	1.1B
ADICON HOLDINGS LIMITED	-11.96%	1.03B

Medical & Diagnostic Laboratories